GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange for a 19.9% equity stake and a seat on Orchard’s board. This move is part of GSK’s strategic initiative to refine its focus on core areas such as respiratory, HIV/infectious […]
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic move is set to enhance Novartis’s capabilities in gene therapy and neuroscience, particularly in the treatment of spinal muscular atrophy (SMA). Strategic Acquisition in Pharma Under the agreement, Novartis will […]
In a significant advancement for medical science, Luxturna (voretigene neparvovec), developed by Spark Therapeutics, has been approved by the U.S. Food and Drug Administration (FDA) for treating a rare inherited form of vision loss that affects both children and adults. This condition, associated with mutations in the RPE65 gene, can lead to complete blindness if […]
Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion in an all-cash transaction. This acquisition, priced at $27 per share, significantly bolsters Roche’s oncology portfolio by adding advanced gene therapy-based cancer drugs that are in the early stages of […]
Luxturna FDA approval news : An FDA panel has recommended the approval of Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics for treating a rare form of genetically inherited form of blindness.
In a significant development in gene therapy, Spark Therapeutics’ Luxturna (voretigene neparvovec) is on the verge of receiving FDA approval for treating blindness caused by inherited retinal diseases (IRD), specifically those mediated by the RPE65 gene mutation. This breakthrough follows a unanimous recommendation from the 16-member Cellular, Tissue, and Gene Therapies Advisory Committee of the […]